

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of  
Sefton

Serial No: not yet assigned

Filed: herewith

For: TAZAROTENE AND  
CORTICOSTEROID TREATMENT FOR  
PSORIASIS

Group Art Unit: Not yet assigned  
(Parent Group Art Unit: 1616)

Examiner: Not yet assigned  
(Examiner for parent: Badio, B)

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop: Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits form PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR §§ 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant further points out that the present application is a continuation of United States Patent Application serial number 09/367,712, filed August 18, 1999, and that the prosecution history of said application(s) may contain rejections, decisions by the Board, arguments, references and/or disclosure which are relevant to the patentability of the disclosure made in the present application.

Pursuant to 37 CFR § 1.98(d), copies of any patent publication or other information are not required to be provided if they were previously cited by or submitted to the Patent and Trademark Office in a prior application to which priority is claimed under 35 USC § 120.


Copies of all items indicated in form PTO 1449 have previously been provided to or cited by the Patent and Trademark Office in prior patent application Serial No. 09/367,712,

filed August 18, 1999, priority to which has been claimed under 35 USC § 120 for the present application. There are no newly referenced citations in this Information Disclosure Statement.

Applicant respectfully requests that the Examiner indicate consideration of the cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

As this Information Disclosure Statement is being submitted with this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,



Brent A. Johnson  
Registration No. 51,851  
Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson  
Allergan, Inc.  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714/246-4348  
Telecopier: 714/246-4249

**CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10**

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on **April 7, 2004** in an envelope as "Express Mail Post Office To Addressee" mailing label number **EV193721147US** with sufficient postage for Express Mail addressed to Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew  
Name of person mailing paper



Susan Bartholomew  
Signature of person mailing paper

Date: April 7, 2004

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	Not yet assigned
		Filing Date	Herewith
		First Named Inventor	Sefton
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet	1	of	2
		Attorney Docket Number	

**U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	Not yet assigned
				Filing Date	Herewith
				First Named Inventor	Sefton
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	2	Attorney Docket Number	17224

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Schwartz, Biological Abstracts, vol. 10, Philadelphia, PA, US; abstract no. 981998 & Journal of Investigative Dermatology, 102 (2). 1994. 241-246			
		Ban Der Rhee, Biological Abstracts, vol. 31, Philadelphia, PA, US; abstract no. 16902 & BR J DERMATOL, 102 (2) 1980. 203-212.			
		CHUN, "Inclusion complexation of hydrocortisone butyrate ...." International Journal of Pharmaceutics, 96 (Jul 31), pp. 91-103.			
		LEHNER ET AL, (1994), "Interactions between preservatives and 2-hydroxypropyl b-cyclodextrin." Drug Development and Industrial Pharmacy, 18 (13), pp. 1477-84.			
		VIANNA ET AL, (1998), "Formation of cyclodextrin inclusion complexes with corticosteroids..." International Journal of Pharmaceutics, 167 (Jun 1), pp. 206-213.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.